Figure 3From: Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trialsCombined results according to sensitivity analysis - Secondary outcomes. CI: confidence interval; ORR: overall response rate; PR: partial response rate; BEVA: bevacizumab.Back to article page